News Related to S&P Global

Related coverage linked through entity extraction aliases.

Johnson & Johnson projects about $100.5 billion in 2026 revenue amid litigation and patent headwinds

Apr 11, 2026

Johnson & Johnson said revenue could reach about $100.5 billion at the midpoint in 2026 after 2024 net sales rose 6% to $94.2 billion. The company faces talc litigation, Stelara patent losses and U.S. drug price negotiations.

Lupin Reports 26% Revenue Growth in Q3 FY26, Receives FDA Approval for Biosimilar Pegfilgrastim

Feb 24, 2026

Lupin Limited reported strong Q3 FY26 results with total sales of ₹71,005 million, up 26% year-over-year, and received US FDA approval for its pegfilgrastim biosimilar Armlupeg™, which has not yet been launched.